Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
Portfolio Pulse from
Telix Pharmaceuticals has received approval from Brazil's ANVISA for Illuccix®, a prostate cancer imaging agent. This marks the first marketing authorization for Illuccix® in Latin America.
March 18, 2025 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Telix Pharmaceuticals' Illuccix® has been approved by ANVISA for prostate cancer imaging in Brazil, marking its first marketing authorization in Latin America.
The approval of Illuccix® by ANVISA allows Telix Pharmaceuticals to enter the Brazilian market, potentially increasing its revenue and market presence in Latin America. This is a significant milestone for the company, as it is the first PSMA-PET prostate cancer imaging agent to receive full regulatory approval in Brazil.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100